These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8981549)

  • 1. Pharmacology of the hypoglycaemic sulphonylurea gliquidone. III. Conformational analysis.
    Lins L; Brasseur R; Malaisse WJ
    Pharmacol Res; 1996; 34(1-2):9-10. PubMed ID: 8981549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
    Lins L; Brasseur R; Malaisse WJ
    Biochem Pharmacol; 1995 Nov; 50(11):1879-84. PubMed ID: 8615868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents.
    Cai Z; Lansdell KA; Sheppard DN
    Br J Pharmacol; 1999 Sep; 128(1):108-18. PubMed ID: 10498841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiaggregatory activity of hypoglycaemic sulphonylureas.
    Siluk D; Kaliszan R; Haber P; Petrusewicz J; Brzozowski Z; Sut G
    Diabetologia; 2002 Jul; 45(7):1034-7. PubMed ID: 12136403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of the sulphonylurea antidiabeticum gliquidone with mitochondrial bioenergetics in the rat under in vitro conditions.
    Somogyi J; Vér A; Trója G; Végh E; Bühler C; Hatfaludi F; Csermely P; Popović S
    Acta Physiol Hung; 1995; 83(4):299-312. PubMed ID: 8863893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of action of peroral antidiabetics. Sulfonylurea preparations block the ATP-dependent potassium channels].
    Larsson O; Kindmark H; Bränström R; Berggren PO
    Lakartidningen; 1997 Nov; 94(48):4473-7. PubMed ID: 9424548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide and related hypoglycemic benzoic acid derivatives.
    Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
    J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR study of some anti-hyperglycaemic sulphonylurea drugs.
    Dearden JC; Hewitt M; Rowe PH
    SAR QSAR Environ Res; 2015 Jun; 26(6):439-48. PubMed ID: 26034813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of sulphonylurea antidiabetica with mitochondrial bioenergetics under in vivo conditions.
    Somogyi J; Vér A; Trója G; Végh E; Bányász T; Csermely P; Popović S; Kovács T
    Acta Physiol Hung; 1995; 83(4):313-21. PubMed ID: 8863894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of hypoglycaemic sulphonylureas and antibiotic ionophores upon calcium translocation.
    Couturier E; Malaisse WJ
    Br J Pharmacol; 1980; 71(1):315-20. PubMed ID: 6781574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of first and second generation sulphonylureas on cardiotoxicity of strophanthidin in rabbits.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res; 1989 Dec; 12(4):193-7. PubMed ID: 2637095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.
    Jojima T; Suzuki K; Hirama N; Uchida K; Hattori Y
    Diabetes Obes Metab; 2009 Feb; 11(2):143-9. PubMed ID: 18564176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs.
    Mark M; Grell W
    Br J Pharmacol; 1997 Aug; 121(8):1597-604. PubMed ID: 9283692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of hypoglycemic sulfonylureas and negative phospholipids on calcium transport: ionic and conformational aspects.
    Deleers M; Grognet P; Mahy M; Brasseur R; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1983 Sep; 41(3):407-24. PubMed ID: 6635329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.
    Steri R; Kara M; Proschak E; Steinhilber D; Schneider G; Schubert-Zsilavecz M
    Future Med Chem; 2010 Apr; 2(4):575-86. PubMed ID: 21426008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family.
    Malaisse WJ
    Horm Metab Res; 1995 Jun; 27(6):263-6. PubMed ID: 7557835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation between the potency and reversibility of the insulinotropic action of two meglitinide analogues.
    Jijakli H; Ulusoy S; Malaisse WJ
    Pharmacol Res; 1996; 34(3-4):105-8. PubMed ID: 9051699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
    Koltai MZ
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
    Löffler C; Quast U
    Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ionophoretic properties of the non-sulfonylurea hypoglycemic agents A-4166 and KAD-1229.
    Bakkali-Nadi A; Malaisse-Lagae F; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1995 Jun; 88(3):339-47. PubMed ID: 8564389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.